Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EXACT Therapeutics AS ( (DE:56F) ) has shared an announcement.
EXACT Therapeutics and Cordance Medical have announced promising early results from studies showing significantly increased uptake of a radiopharmaceutical in brain tumors using their combined technologies. This development opens possibilities for broader applications in treating brain diseases by temporarily increasing blood-brain barrier permeability and enhancing therapeutic delivery. The findings highlight the potential of ACT® technology in oncology, reinforcing EXACT Therapeutics’ focus on cancer therapy, with ongoing experiments to validate these results further.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that focuses on using ultrasound and microbubbles for targeted drug delivery in oncology. The company is exploring its proprietary Acoustic Cluster Therapy (ACT®) across various therapeutic areas, including brain diseases. Cordance Medical is a pioneer in non-invasive medical technologies, particularly for brain disease treatment, and offers the NeuroAccess™ platform to enhance patient outcomes globally.
YTD Price Performance: -10.45%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €18.78M
Find detailed analytics on 56F stock on TipRanks’ Stock Analysis page.